Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis

被引:16
|
作者
Hogan, Julien [1 ]
Godron, Astrid [2 ]
Baudouin, Veronique [1 ]
Kwon, Theresa [1 ]
Harambat, Jerome [2 ]
Deschenes, Georges [1 ]
Niel, Olivier [1 ]
机构
[1] Robert Debre Hosp, AP HP, Pediat Nephrol Dept, Paris, France
[2] Bordeaux Univ, Pediat Nephrol Unit, Pellegrin Enfants Hosp, Bordeaux, France
关键词
Lupus nephritis; Children; Rituximab; Steroid minimization; INTRAVENOUS CYCLOPHOSPHAMIDE; ERYTHEMATOSUS; CHILDREN; EFFICACY; ADOLESCENTS; MANAGEMENT; STEROIDS; DISEASE;
D O I
10.1007/s00467-017-3767-4
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
In clinical trials, the addition of rituximab (RTX) to the combination therapeutic regimen of mycophenolate mofetil (MMF) and corticosteroids failed to improve outcome in lupus nephritis (LN). However, recent data suggest that RTX may have steroid-sparing beneficial effects with an efficacy similar to that of conventional regimens. We report our experience with RTX in the treatment of children with LN. Patients treated with RTX for first occurrence of LN class III to V were enrolled in the study. Treatment consisted of methylprednisolone pulse (500 mg/m(2)) followed by RTX (1000 mg/1.73 m(2)) at days 1 and 15, and MMF (1200 mg/m(2)/day). Prednisolone tapering and withdrawal was left to the physician's discretion. Complete remission (CR) was defined as a urine protein-to-creatinine ratio (U Pr/Cr) of < 5 mg/mg and normal serum creatinine, and partial remission (PR) as a U Pr/Cr of < 30 mg/mg and a < 15% rise in serum creatinine over baseline. Twelve patients were included in the study, with median follow-up of 23.7 [interquartile range (IQR) 12.8-33.5] months. Median age of the patients was 13.6 [12.3-15.1] years, median proteinuria was 32 [19-67] mg/mg and median estimated glomerular filtration rate was 76.1 [59.3-97.7] mL/min/1.73 m(2). Median CD20 depletion duration was 10 [6.8-11.0] months. Prednisolone was rapidly tapered, with median dose of 0.3 [0.15-0.41], 0.10 [0.09-0.16] and 0.0 [0.0-0.04] mg/kg/day at 3, 6 and 12 months respectively. At 3 months, three and seven patients achieved CR and PR, respectively; at 6 and 12 months all patients achieved remission (9 CR, 3 PR) and none relapsed during follow-up. Five infectious complications were observed, including three varicella-zoster virus (VZV) infections. In our pediatric patients with LN, therapy with RTX + MMF combined with a rapid decrease in steroid appears to have been an efficacious treatment for severe LN but was associated with high rate of VZV infection. The potential of RTX to allow complete steroid avoidance warrants further investigation in children.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 50 条
  • [21] Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis
    Kizawa, Toshitaka
    Nozawa, Tomo
    Kikuchi, Masako
    Nagahama, Kiyotaka
    Okudela, Koji
    Miyamae, Takako
    Imagawa, Tomoyuki
    Nakamura, Tomoko
    Mori, Masaaki
    Yokota, Shumpei
    Tsutsumi, Hiroyuki
    MODERN RHEUMATOLOGY, 2015, 25 (02) : 210 - 214
  • [22] Mycophenolate mofetil as induction and maintance therapy of lupus nephritis - our experience
    Raskovic, S.
    Peric-Popadic, A.
    Jovicic, Z.
    Tomic-Spiric, V
    Sojic-Rajcic, J.
    Stefanovic, L.
    Bogic, M.
    ALLERGY, 2010, 65 : 464 - 464
  • [23] Membranous lupus nephritis in a renal allograft: Response to mycophenolate mofetil therapy
    Denton, MD
    Galvanek, EG
    Singh, A
    Sayegh, MH
    AMERICAN JOURNAL OF TRANSPLANTATION, 2001, 1 (03) : 288 - 292
  • [24] Mycophenolate Mofetil is an Effective Induction Therapy Agent in Childhood-onset Pure Membranous Lupus Nephritis
    Pereira, Maria
    Muscal, Eyal
    DeGuzman, Marietta
    Sagcal-Gironella, Anna Carmela
    Wenderfer, Scott E.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 : 139 - 141
  • [25] Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide
    Christian Burchardi
    Detlef Schlöndorff
    Nature Clinical Practice Nephrology, 2006, 2 : 314 - 315
  • [26] What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?
    Jones, Rachel B.
    Walsh, Michael
    Smith, Kenneth G. C.
    CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (03) : 256 - 261
  • [27] Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide
    Jennifer R Elliott
    Susan Manzi
    Nature Clinical Practice Rheumatology, 2006, 2 : 354 - 355
  • [28] Mycophenolate mofetil seems to be superior to Azothioprine in Maintenance therapy of Lupus nephritis
    Schmalzing, M.
    Koetter, I.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2012, 71 (09): : 813 - 815
  • [29] Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ginzler, EM
    Dooley, MA
    Aranow, C
    Kim, MY
    Buyon, J
    Merrill, JT
    Petri, M
    Gilkeson, GS
    Wallace, DJ
    Weisman, MH
    Appel, GB
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21): : 2219 - 2228
  • [30] Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study
    Park, D-J
    Kang, J-H
    Lee, K-E
    Bae, S-C
    Chung, W-T
    Choe, J-Y
    Jung, S-Y
    Kim, Y-S
    Lee, H-S
    Lee, J.
    Lee, Y-A
    Park, S-H
    Park, Y-J
    Suh, C-H
    Yoo, D-H
    Lee, S-S
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (01) : 89 - 96